References
- Conti F, Ceccarelli F, Massaro L, et al. Biological therapies in rheumatic diseases. Clin Ter. 2013;164(5):e413–428. doi:10.7417/CT.2013.1622.
- Vanamee ES, Faustman DL. Structural principles of tumor necrosis factor superfamily signaling. Sci Signal. 2018; 11(511): doi: 10.1126/scisignal.aao4910.
- Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26:471–475.
- Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: a state of the art review. Autoimmun Rev. 2017;16(10):1008–1015. doi:10.1016/j.autrev.2017.07.014.
- Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48(8):883–886. doi:10.1093/rheumatology/kep046.
- Tong D, Manolios N, Howe G, Spencer D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J. 2012;42(1):89–94. doi:10.1111/j.1445-5994.2011.02612.x.
- Canas CA, Tobon GJ, Arango LG, Guarin N. Developing of granulomatous thyroiditis during etanercept therapy. Clin Rheumatol. 2009;28(Suppl S1):S17–19. doi:10.1007/s10067-008-1046-2.
- Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol. 2008;35:349–351.
- Ortiz-Sierra MC, Echeverri AF, Tobon GJ, Canas CA. Developing of granulomatosis with polyangiitis during etanercept therapy. Case Rep Rheumatol. 2014;2014:210108. doi:10.1155/2014/210108.
- Levine SD, Robinson M, Honda K, Nedorost S. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis. 2009;83:50.
- Ngoufack C, Semerano L, Podglajen I, et al. Mitral valve granulomatosis: a paradoxical reaction complicating etanercept treatment in rheumatoid arthritis. A case report. Joint Bone Spine. 2021;88(4):105183. doi:10.1016/j.jbspin.2021.105183.
- Decock A, Van Assche G, Vermeire S, Wuyts W, Ferrante M. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohn’s Colitis. 2017;11(3):378–383. doi:10.1093/ecco-jcc/jjw155.
- Skoie IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int. 2012;32(4):1049–1053. doi:10.1007/s00296-009-1349-x.
- González-López MA, Blanco R, González-vela MC, Fernández-llaca H, Rodríguez-valverde V. Development of sarcoidosis during etanercept therapy. Arthritis & Rheumatism. 2006;55(5):817–820. doi:10.1002/art.22238.
- Idowu OO, Saifee M, Copperman TS, Kersten RC. Dacryoadenitis associated with juvenile idiopathic arthritis. Ophthalmic Plast Reconstr Surg. 2020;36(3):e63–e65. doi:10.1097/IOP.0000000000001573.
- Rathmell JP, Shields CL, Shields JA, Eagle RC, Gordon RD. Chronic dacryoadenitis associated with juvenile rheumatoid arthritis. Orbit. 1988;7(2):95–100. doi:10.3109/01676838809036134.
- Mahdaviani S, Higgins GC, Kerr NC. Orbital pseudotumor in a child with juvenile rheumatoid arthritis. J Pediatric Ophthalmol Strabismus. 2005;42(3):185–188. doi:10.3928/01913913-20050501-09.